|
Market Closed -
NYSE
16:00:00 2026-10-23 EDT
|
5-day change | 1st Jan Change | ||
| 1.520 USD | -5.00% |
|
+34.51% | +11.76% |
Company Valuation: Actinium Pharmaceuticals, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 132.4 | 271.4 | 139.3 | 39.31 | 42.43 | 47.79 | - | - |
| Change | - | 104.97% | -48.69% | -71.77% | 7.94% | 12.64% | - | - |
| Enterprise Value (EV) | 132.4 | 271.4 | 62.58 | 39.31 | 42.43 | 47.79 | 47.79 | 47.79 |
| Change | - | 104.97% | -76.94% | -37.19% | 7.94% | 12.64% | 0% | 0% |
| P/E | -5.01x | -7.77x | -2.78x | -0.99x | -1.25x | 8.6x | -2.27x | -3.92x |
| PBR | 1.81x | - | 3.72x | - | - | - | - | - |
| PEG | - | -0.5x | -0.1x | 0x | 0.1x | -0x | 0x | 0.1x |
| Capitalization / Revenue | 116x | 263x | 1,719x | - | 471x | 2.73x | - | 2.74x |
| EV / Revenue | 0x | 0x | 0x | - | 0x | 2.73x | - | 2.74x |
| EV / EBITDA | -0x | -0x | -0x | -0x | -0x | 19.9x | -1.29x | -1.16x |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | 9.19x | -1.43x | -2.13x |
| EV / FCF | -0x | 0x | -0x | -0x | - | 2.21x | -1.77x | -1.97x |
| FCF Yield | -15.9% | 3.05% | -34.1% | -84.2% | - | 45.2% | -56.5% | -50.8% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -1.2 | -1.37 | -1.83 | -1.27 | -1.09 | 0.1767 | -0.67 | -0.3875 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 1.144 | 1.03 | 0.081 | - | 0.09 | 17.5 | - | 17.46 |
| EBITDA 1 | -24.44 | -33.4 | -51.13 | -41.31 | -35.43 | 2.4 | -37.1 | -41.1 |
| EBIT 1 | -24.96 | -34.1 | -51.92 | -42.12 | -36.25 | 5.201 | -33.35 | -22.45 |
| Net income 1 | -24.77 | -33.02 | -48.82 | -38.24 | -33.89 | 5.912 | -30.95 | -19.95 |
| Net Debt | - | - | -76.68 | - | - | - | - | - |
| Reference price 2 | 6.010 | 10.650 | 5.080 | 1.260 | 1.360 | 1.520 | 1.520 | 1.520 |
| Nbr of stocks (in thousands) | 22,031 | 25,483 | 27,413 | 31,196 | 31,196 | 31,441 | - | - |
| Announcement Date | 3/25/22 | 3/31/23 | 3/29/24 | 3/31/25 | 3/30/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 9.06x | - | - | - | 43.39M | |
| 18.38x | 6.48x | 12.88x | 1.62% | 63.29B | |
| 30.22x | 7.94x | 26.49x | 0.05% | 54.89B | |
| 36.58x | 6.5x | 19.41x | 0.88% | 53.28B | |
| 35.46x | 3.44x | 14.83x | -.--% | 45.81B | |
| 50.32x | 5.82x | 31.95x | -.--% | 43.46B | |
| -19.48x | 188.5x | -20.74x | -.--% | 40.23B | |
| 29.02x | 8.23x | 21.28x | 0.37% | 33.45B | |
| 27.38x | 5.77x | 14.95x | -.--% | 23.7B | |
| 32.79x | 5.99x | 20.16x | -.--% | 23.76B | |
| Average | 24.97x | 26.52x | 15.69x | 0.32% | 38.19B | |
| Weighted average by Cap. | 26.70x | 25.51x | 15.93x | 0.43% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- ATNM Stock
- Valuation Actinium Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
